Register For Our Webinar

"Antibodies and Antibody-Drug Conjugate Higher Order Structures Revealed"

Webinar Length: 1 hour

Broadcast Date: Tuesday, November 13th, 2018

Time: 8:00 am PT, 11:00 am ET, 17:00 CET

Host: Genetic Engineering News

Speakers

Shah_Karan

Karan Shah

Principal Development Associate, ImmunoGen, Inc.
Papayannopoulos_photo

Ioannis Papayannopoulos Ph.D.

Senior Scientist III Celldex Therapeutics
eugene-ma

Eugene Ma

Co-Founder and Chief Technology Officer, RedShiftBio

Recently investigators have begun to harness new technology such as microfluidic modulation spectroscopy (MMS) to reveal protein structural changes, as a solid understanding of structure and function is extremely important to the effectiveness of biotherapeutic drugs and scientist today are challenged in gathering a complete understanding with current tools During the biomanufacturing process, proteins such as antibodies, often undergo conformational changes that can alter their secondary structure, leading to critical variations in their overall function. These changes have been historically difficult to detect, as traditional analytical techniques are not great at detecting small differences in protein structure. MMS however, can detect these changes with great sensitivity and accuracy without the need for dilution or chemical alteration. Moreover, MMS offers detailed information on which structural motifs in the protein molecule are changing, providing more guidance to scientists in their efforts to develop more stable antibody molecules and formulations. Join us for this new GEN webinar where we will learn how MMS technology is making a significant impact toward understanding the structures of therapeutic antibodies and antibody drug conjugates.

Learning Objectives:

  • How Microfluidic Modulation Spectroscopy (MMS) can be used to understand the structures of therapeutic antibodies and antibody drug conjugates
  • Introduction to the AQS3™pro MMS system from RedShiftBio

Webinar Highlights:

  • Characterization of mAb’s and ADC’s without the need for dilutions or concern for your formulation buffer’s excipient interferences, enabled by MMS, is critical to understand the TRUE structure of your drug product at the intended therapeutic conditions.
  • Microfluidic Modulation Spectroscopy provides a reliable platform with increased sensitive and higher resolution for secondary structure analysis of biotherapeutics.
  • MMS’s Automated walk away workflow makes it applicable for screening studies much earlier in the development process.

Speakers:

Karan K. Shah is a Principal Development Associate in the Analytical and Pharmaceutical Sciences department at ImmunoGen, Inc.

He received his M.S. in Pharmaceutical Sciences from Northeastern University and is an analytical chemist with several years of experience in the biopharmaceutical industry. His R&D experience includes formulation development as well as analysis and characterization of antibodies and antibody drug conjugates (ADCs). He has expertise in method development for characterization of antibodies and ADCs using a broad spectrum of analytical and biophysical techniques and in the application of these techniques to support CMC development.

Ioannis Papayannopoulos

has been carrying out peptide and protein analytical work for the past several decades, using mass spectrometry, chromatography, spectroscopy, and other analytical techniques. He received his undergraduate degree in chemistry from Bowdoin College and his PhD in Organic Chemistry from the Massachusetts Institute of Technology, where he conducted research in mass spectrometry under the supervision of the late professor KlausBiemann. Over the years Dr. Papayannopoulos has alternated between academia, most recently as director of the Proteomics Facility at the Koch Institute for Integrative Cancer Research at MIT, and the biopharmaceutical industry in senior scientific and management roles at companies such as Biogen, Covance and AstraZeneca. For the past several years he has been with Celldex Therapeutics, a biopharmaceutical company in Massachusetts, working on the analysis and characterization of antibodies, antibody-drug conjugates and recombinant protein pharmaceuticals

Eugene Ma, Co-Founder and Chief Technology Officer, RedShiftBio

Eugene, CTO of RedShiftBio, is responsible for technology innovation and technical support across the full range of activities at RedShiftBio. Eugene has a BSEE from Yale University, and a MA and PhD in electrical engineering from Princeton University. He has also studied business at the Wharton School, University of Pennsylvania.